In the global fight against cancer, early detection remains one of the most critical and challenging frontiers. Creatv Bio is at the forefront of addressing this challenge, pioneering breakthrough technologies that aim to detect, monitor, and understand cancer through a simple blood test. As a division of Creatv MicroTech, Inc., the company is redefining how cancer is diagnosed and managed, bringing a new level of precision and accessibility to oncology.
With a mission centered on “detecting and diagnosing cancer when it matters most,” Creatv Bio is focused on saving and improving lives through innovative diagnostic solutions that eliminate the need for invasive procedures.
A Vision Rooted in Early Detection
Creatv Bio’s vision is grounded in a powerful belief: that cancer outcomes can be dramatically improved if the disease is identified earlier and monitored more effectively. The company’s technologies are designed not only to detect cancer but also to provide actionable insights into treatment response, disease progression, and patient prognosis.
Unlike traditional diagnostic methods that rely heavily on tissue biopsies, which can be invasive and limited in scope, Creatv Bio’s approach leverages liquid biopsy—a non-invasive technique that analyzes cancer-related components circulating in the bloodstream. This shift represents a fundamental change in oncology, enabling continuous monitoring and more dynamic decision-making throughout a patient’s treatment journey.
The Science Behind the Innovation
At the heart of Creatv Bio’s platform is its proprietary CellSieve™ microfilter technology, a breakthrough innovation that enables the isolation of cancer-associated cells directly from a small blood sample. This technology forms the foundation of the company’s flagship test, LifeTracDx®, a liquid biopsy designed to capture a comprehensive range of tumor-related cells.
The process is both elegant and highly efficient. Using a specially engineered microfilter, the system removes red blood cells and more than 99.9% of white blood cells, isolating cancer-associated cells from just 7 mL of blood in minutes. These cells are then stained and analyzed under a microscope, providing critical information about tumor biology.
What sets Creatv Bio apart is its ability to detect a broader spectrum of cancer-associated cells—not just traditional circulating tumor cells (CTCs), but also more advanced and informative biomarkers such as Tumor-Macrophage Hybrid Cells (TMHCs) and Cancer-Associated Macrophage-Like Cells (CAMLs).
CAMLs: A Breakthrough Biomarker
One of Creatv Bio’s most significant scientific contributions is the discovery and validation of CAMLs. These unique cells, found in the bloodstream of cancer patients but not in healthy individuals, offer a powerful new biomarker for cancer detection and monitoring.
Unlike CTCs, which are typically associated with late-stage cancers and limited to specific cancer types, CAMLs are present across all stages of cancer and in more than 30 different cancer types analysed so far. This makes them a far more versatile and reliable indicator of disease presence and progression.
CAMLs also provide rich biological information. They contain many copies of whole tumor DNA and proteins, enabling researchers and clinicians to assess DNA mutations, amplifications and deletions, identify drug targets, and evaluate treatment effectiveness—all from a simple blood draw.
Transforming Cancer Diagnostics and Monitoring
Creatv Bio’s liquid biopsy platform has wide-ranging applications across the cancer care continuum. From early screening to post-treatment monitoring, the company’s technology supports a more comprehensive and personalized approach to oncology.
One of its key advantages is the ability to detect cancer recurrence and residual disease earlier than traditional imaging methods. By identifying cancer-associated cells in the bloodstream, clinicians can gain early warning signs of disease progression and adjust treatment strategies accordingly.
The platform also enables real-time monitoring of therapy response. In many cases, treatment effectiveness can be assessed within weeks, allowing for faster optimization of therapeutic approaches.
Additionally, the technology plays a crucial role in determining cancer aggressiveness. Specific cellular features—such as cell size, clustering, and molecular markers—provide valuable insights into how the disease is likely to behave, helping guide clinical decisions.
Enabling Precision Medicine and Drug Development
Beyond clinical diagnostics, Creatv Bio is making a significant impact in biopharmaceutical research and drug development. Its platform can develop companion diagnostics for the cancer drugs, helping identify which patients are most likely to benefit from specific therapies based on the results of companion diagnostics of their cancer and CTCs and CAMLs found in the LifeTracDx® assay.
The ability to monitor biomarkers such as PD-L1 expression over time is particularly valuable in immunotherapy, where treatment response can vary significantly. Creatv Bio’s approach allows for continuous tracking of these markers, providing a dynamic view of how tumors evolve during treatment.
Moreover, the company’s technology facilitates clinical trial recruitment and evaluation by identifying suitable candidates and tracking outcomes with greater precision. This not only accelerates drug development but also improves the likelihood of successful therapeutic outcomes.
A Legacy of Innovation
As part of Creatv MicroTech, Creatv Bio benefits from a legacy of excellence in microfabrication and diagnostics. The parent company has received prestigious accolades, including the R&D 100 Award and recognition as Biotech Company of the Year in Montgomery County, Maryland.
This heritage underscores the company’s commitment to pushing technological boundaries and delivering impactful solutions that address real-world challenges.
Shaping the Future of Cancer Care
Looking ahead, Creatv Bio is poised to play a transformative role in the future of oncology. Its non-invasive, data-rich approach to cancer detection and diagnostics, and monitoring aligns with the broader shift toward precision medicine—where treatments are tailored to individual patients based on detailed biological insights.
As healthcare systems worldwide seek more efficient, cost-effective, and patient-friendly diagnostic tools, liquid biopsy technologies like those developed by Creatv Bio are gaining increasing importance. By enabling earlier detection, continuous monitoring, and more informed decision-making, the company is helping redefine the standard of cancer care.
In a field where timing can mean the difference between life and death, Creatv Bio’s innovations offer a powerful promise: to detect cancer earlier, treat it smarter, and ultimately improve outcomes for patients around the world.
Cha-Mei Tang, Founder, President, and CEO
Cha-Mei Tang is the Founder, President, and CEO of Creatv Bio, leading innovation in cancer diagnostics through advanced liquid biopsy technologies. She holds BS, MS, and ScD degrees in Electrical Engineering from Massachusetts Institute of Technology and has conducted research at the Naval Research Laboratory and as a visiting scientist at National Institute of Standards and Technology.
An accomplished innovator, she has filed 18 U.S. and international patents (57 issued) and authored 163 scientific publications. Her recognitions include Fellow of the American Physical Society (1990), the WISE Award (1992), Senior Member of Institute of Electrical and Electronics Engineers (1995), the R&D 100 Award (2006), and listings in Marquis Who’s Who (2024) and Continental Who’s Who (2025).
“We aim to use our blood test technologies to support cancer research, offer insights for treatment planning, assist in monitoring response, and help explore factors related to prognosis.”
